TW200716605A - 2,6-quinolinyl derivatives, processes for preparing them and their uses - Google Patents

2,6-quinolinyl derivatives, processes for preparing them and their uses

Info

Publication number
TW200716605A
TW200716605A TW095119798A TW95119798A TW200716605A TW 200716605 A TW200716605 A TW 200716605A TW 095119798 A TW095119798 A TW 095119798A TW 95119798 A TW95119798 A TW 95119798A TW 200716605 A TW200716605 A TW 200716605A
Authority
TW
Taiwan
Prior art keywords
preparing
processes
quinolinyl derivatives
quinolinyl
derivatives
Prior art date
Application number
TW095119798A
Other languages
English (en)
Inventor
Benjamin Perry
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0511781A external-priority patent/GB0511781D0/en
Priority claimed from GB0600213A external-priority patent/GB0600213D0/en
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of TW200716605A publication Critical patent/TW200716605A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095119798A 2005-06-09 2006-06-05 2,6-quinolinyl derivatives, processes for preparing them and their uses TW200716605A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0511781A GB0511781D0 (en) 2005-06-09 2005-06-09 2,6-quinolinyl derivatives, processes for preparing them and their uses
US20615805A 2005-08-18 2005-08-18
GB0600213A GB0600213D0 (en) 2006-01-06 2006-01-06 2,6-quinolinyl derivatives, processes for preparing them and their uses

Publications (1)

Publication Number Publication Date
TW200716605A true TW200716605A (en) 2007-05-01

Family

ID=36968449

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095119798A TW200716605A (en) 2005-06-09 2006-06-05 2,6-quinolinyl derivatives, processes for preparing them and their uses

Country Status (19)

Country Link
US (1) US7732614B2 (zh)
EP (1) EP1902045B1 (zh)
JP (1) JP2008542407A (zh)
KR (1) KR20080021085A (zh)
AR (1) AR054129A1 (zh)
AT (1) ATE496041T1 (zh)
AU (1) AU2006254772B2 (zh)
BR (1) BRPI0611243A2 (zh)
CA (1) CA2610800A1 (zh)
DE (1) DE602006019731D1 (zh)
EA (1) EA013080B1 (zh)
IL (1) IL187235A0 (zh)
MX (1) MX2007014721A (zh)
MY (1) MY140739A (zh)
NO (1) NO20080125L (zh)
NZ (1) NZ563739A (zh)
PE (1) PE20070081A1 (zh)
TW (1) TW200716605A (zh)
WO (1) WO2006131200A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE384699T1 (de) 2002-04-30 2008-02-15 Ucb Pharma Sa 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN101102792A (zh) * 2004-11-19 2008-01-09 比奥根艾迪克Ma公司 治疗多发性硬化
KR20080021085A (ko) 2005-06-09 2008-03-06 유씨비 파마, 에스.에이. 2，6 퀴놀리닐 유도체, 이들을 제조하는 방법 및 이들의약제로서의 용도
WO2008125215A1 (en) * 2007-04-12 2008-10-23 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
CA2758548A1 (en) * 2009-04-17 2010-10-21 Biogen Idec Ma Inc. Compositions and methods to treat acute myelogenous leukemia
PL2558499T3 (pl) 2010-04-16 2017-10-31 Biogen Ma Inc Przeciwciała anty-VLA-4
MY160723A (en) * 2013-12-30 2017-03-15 Univ Putra Malaysia An anticoagulant
USD812958S1 (en) 2016-06-08 2018-03-20 Samsung Electronics Co., Ltd. Cooktop
WO2019200202A1 (en) 2018-04-12 2019-10-17 Morphic Therapeutic, Inc. Antagonists of human integrin (alpha4)(beta7)
EP3800999A4 (en) 2018-06-04 2022-06-01 Biogen MA Inc. ANTI-VLA-4 ANTIBODIES WITH REDUCED EFFECTOR FUNCTION
CA3115830C (en) * 2018-10-30 2023-09-12 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
AU2019373240B2 (en) 2018-10-30 2023-04-20 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
JP7214882B2 (ja) 2018-10-30 2023-01-30 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
JP7437490B2 (ja) 2019-10-16 2024-02-22 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリン（アルファ－４）（ベータ－７）の阻害

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0798291B1 (en) 1994-12-14 2002-09-11 Santen Pharmaceutical Co., Ltd. Novel 1,3-dialkylurea derivatives
CA2301377C (en) 1997-08-22 2009-10-06 F. Hoffmann-La Roche Ag N-aroylphenylalanine derivatives
DE69934238T2 (de) 1998-08-26 2007-06-21 Aventis Pharma Ltd., West Malling Azabicyclo-verbindungen welche die inhibition der zell adhesion modulieren
JP2002543194A (ja) 1999-04-28 2002-12-17 ドクター・レディーズ・ラボラトリーズ・リミテッド 置換二環系ヘテロ環化合物、その製造方法、並びに抗肥満症及び抗高コレステロール血症剤としてのこれらの使用
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
ATE384699T1 (de) * 2002-04-30 2008-02-15 Ucb Pharma Sa 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
US7153870B2 (en) 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0329584D0 (en) 2003-12-20 2004-01-28 Tanabe Seiyaku Co Novel compounds
KR20080021085A (ko) 2005-06-09 2008-03-06 유씨비 파마, 에스.에이. 2，6 퀴놀리닐 유도체, 이들을 제조하는 방법 및 이들의약제로서의 용도

Also Published As

Publication number Publication date
EP1902045A1 (en) 2008-03-26
AR054129A1 (es) 2007-06-06
EP1902045B1 (en) 2011-01-19
PE20070081A1 (es) 2007-02-15
DE602006019731D1 (de) 2011-03-03
WO2006131200A1 (en) 2006-12-14
MY140739A (en) 2010-01-15
AU2006254772A1 (en) 2006-12-14
BRPI0611243A2 (pt) 2010-08-24
IL187235A0 (en) 2008-02-09
EA013080B1 (ru) 2010-02-26
CA2610800A1 (en) 2006-12-14
KR20080021085A (ko) 2008-03-06
JP2008542407A (ja) 2008-11-27
EA200702589A1 (ru) 2008-06-30
NZ563739A (en) 2009-12-24
NO20080125L (no) 2008-01-08
ATE496041T1 (de) 2011-02-15
MX2007014721A (es) 2008-02-14
US20070004775A1 (en) 2007-01-04
AU2006254772B2 (en) 2011-06-02
US7732614B2 (en) 2010-06-08

Similar Documents

Publication Publication Date Title
TW200716605A (en) 2,6-quinolinyl derivatives, processes for preparing them and their uses
JO2578B1 (en) Compounds Theophene benzimidazole
TWI268278B (en) 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses
EP2308870A3 (en) 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
WO2007065595A3 (en) Xanthine derivatives, processes for preparing them and their uses
TW200508197A (en) Indolone-acetamide derivatives, processes for preparing them and their uses
TW200608973A (en) Rapamycin polymorph Ⅱ and uses thereof
TW200800999A (en) Novel compounds
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
TW200738659A (en) Novel compounds
DE602004021472D1 (en) Pyrimiidinverbindungen
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
TW200612892A (en) Novel compounds
TW200638930A (en) Acetylene derivatives
TW200732296A (en) Novel compounds
IL176142A (en) Processes for preparing montelukast sodium
GB0508314D0 (en) Organic compounds
TWI315305B (en) Piperidin-4-yl-amide derivatives,pharmaceutical compositions comprising the same,process for preparing the same and the use thereof
ZA200800542B (en) 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
WO2007065684A3 (en) Bicyclic heteroyclic compounds as antiinflammatory or antiallergic agents
DE602004024213D1 (en) Aminopropanolderivate
ZA200604410B (en) Imidazole derivatives, processes for preparing them and their uses
SG151306A1 (en) Novel benzothiazoles and the use thereof as medicaments
TW200638932A (en) CCI-779 polymorph and use thereof
MY149864A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties